https://scholars.lib.ntu.edu.tw/handle/123456789/639914
標題: | Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies | 作者: | Chong, Keong Chang, Jack Keng-Jui LEE-MING CHUANG |
關鍵字: | glucagon-like peptide-1 (GLP-1) receptor agonists; insulin icodec; retatrutide; sodium glucose co-transporters 2 (SGLT2) inhibitors; tirzepatide | 公開日期: | 6-一月-2024 | 來源出版物: | The Kaohsiung journal of medical sciences | 摘要: | Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person-centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing glucose for patients with T2DM. A glucose-reduction treatment regimen must consider weight management. Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events. Glucagon-like peptide-1 (GLP-1) receptor agonists allow better control of glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which activate GIP and GLP-1 receptors improve glycemic control and promote greater weight loss than GLP-1 receptor agonists. Several novel drugs are in the clinical development phase. This review pertains to recent advances in pharmacological management of type 2 diabetes. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639914 | ISSN: | 1607551X | DOI: | 10.1002/kjm2.12800 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。